A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma
Authors
Keywords
-
Journal
PHARMACOTHERAPY
Volume 36, Issue 11, Pages e183-e188
Publisher
Wiley
Online
2016-09-26
DOI
10.1002/phar.1839
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).
- (2017) Antoni Ribas et al. JOURNAL OF CLINICAL ONCOLOGY
- Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: Case report
- (2016) Alfred Basilious et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- A Case of Bilateral Uveitis and Papillitis in a Patient Treated with Pembrolizumab
- (2016) Khawla Abu Samra et al. EUROPEAN JOURNAL OF OPHTHALMOLOGY
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Autoimmune Arthropathy and Uveitis as Complications of Programmed Death 1 Inhibitor Treatment
- (2016) Guillermo de Velasco et al. Arthritis & Rheumatology
- Corticosteroids and immune checkpoint blockade
- (2015) Le Min et al. Aging-US
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient
- (2015) Elisabetta Miserocchi et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- Pancreatitis Secondary to Anti–Programmed Death Receptor 1 Immunotherapy Diagnosed by FDG PET/CT
- (2015) Yazan Z. Alabed et al. CLINICAL NUCLEAR MEDICINE
- Safety of pembrolizumab for the treatment of melanoma
- (2015) Juan Martin-Liberal et al. Expert Opinion On Drug Safety
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Outcomes of Changing Immunosuppressive Therapy after Treatment Failure in Patients with Noninfectious Uveitis
- (2014) Lavnish Joshi et al. OPHTHALMOLOGY
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
- (2012) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Constitutive Neuronal Expression of the Immune Regulator, Programmed Death 1 (PD-1), Identified During Experimental Autoimmune Uveitis
- (2009) Ling Chen et al. OCULAR IMMUNOLOGY AND INFLAMMATION
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started